• CME Group recently announced a multi-year exclusive licensing agreement with Morningstar to launch derivatives based on Morningstar equity index benchmarks that underpin over US$3.00 trillion in linked assets.
• This partnership expands the ways investors can use Morningstar’s indexes in risk management and trading, potentially deepening the firm’s role in global markets.
• We’ll now examine how this new derivatives licensing agreement with CME Group could influence Morningstar’s investment narrative and growth profile.

Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

What Is Morningstar's Investment Narrative?

To own Morningstar, you need to believe in the durability of its data, analytics, and indexes as essential tools for investors, even after a share price drop that has far lagged the broader market. The CME Group licensing deal slots neatly into that story: it reinforces Morningstar’s index franchise by attaching derivatives to benchmarks that already anchor more than US$3.00 trillion in linked assets, but it is unlikely to shift near term earnings drivers in a dramatic way. The more immediate catalysts still look internal: execution on AI-enabled platforms like Direct, ongoing integration of PitchBook, and the company’s capital allocation through buybacks and dividends. On the risk side, Morningstar’s high leverage, slower recent earnings momentum, and meaningful insider selling remain key watchpoints, with the CME agreement adding opportunity rather than removing those concerns.

However, Morningstar’s elevated debt load is an important risk investors should not overlook. Morningstar's shares are on the way up, but they could be overextended by 36%. Uncover the fair value now.

Exploring Other Perspectives

Seven fair value views from the Simply Wall St Community span about US$136,900 to US$329,060, underlining just how far apart opinions sit. Set that against Morningstar’s recent underperformance and leveraged balance sheet, and you can see why different investors may read the CME derivatives deal and broader growth outlook in very different ways.

Explore 7 other fair value estimates on Morningstar - why the stock might be worth as much as 77% more than the current price!

Form Your Own Verdict

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Morningstar research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Morningstar research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Morningstar's overall financial health at a glance.

Contemplating Other Strategies?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• The latest GPUs need a type of rare earth metal called Terbium and there are only 26 companies in the world exploring or producing it. Find the list for free.
• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Uncover the next big thing with 25 elite penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.